➤ 510k clearance for all-in-one cloud and browser-based software solution ➤ Final Medicare pricing for FSYX Ocular Pressure Adjusting Pump ➤ First patients dosed in Phase 1b/2a study of potential long-acting anti-VEGF therapy ➤ Topline data for Phase 3 clinical trial for treatment of wet AMD ➤ ASCRS news and events ➤ EyeWorld article of the week
In the past, EyeWorld has delved into nuanced glaucoma subtypes. Here, two physicians discussed traumatic glaucoma, including when it occurs, diagnostic tools, and management options.
When it comes to development and utilization of big data and AI for diagnostic and patient care decisions, there is a lot of work being done in this area to advance glaucoma care to being more proactive rather than reactive. Read what two ophthalmologists had to say on this topic.
Glaucoma specialists say they’re often referred post-cataract surgery patients experiencing an IOP spike, many of whom could be treated by the referring surgeon. EyeWorld spoke with two glaucoma specialists to get their insights on what to watch for and management of these cases.
While the treatment mainstays for lowering and/or maintaining a target IOP are achieved with surgery, laser, or pharmaceuticals, patients often ask what else they can do. Several physicians spoke to EyeWorld about lifestyle changes that they recommend as an addition to traditional glaucoma therapies.
Steroid-induced glaucoma can present a number of issues, most notably increased IOP. Several ophthalmologists discussed identifying when and why this occurs and how to react to help improve the pressure.
Pseudoexfoliation syndrome is a systemic, age-related disease, with patients needing more frequent monitoring due to an increased risk of developing secondary open angle glaucoma from the condition. Two physicians provided their perspectives on the condition and advice for its identification, management, and considerations for surgery.
➤ NDA submitted for epithelium-on crosslinking therapy ➤ Positive results in Phase 2 trial for first-in-class therapy for acute optic neuritis ➤ Study: long-term, real-world findings evaluating standalone canaloplasty and trabeculotomy ➤ Phase 1b study evaluating sozinibercept for DME published ➤ Phase 2 study for topical dry AMD therapy begins ➤ FDA clears IND for gene therapy targeting Stargardt disease ➤ ASCRS news and events
In June 2024, the FDA approved the FSYX Ocular Pressure Adjusting Pump by Balance Ophthalmics, making it the first non-surgical, non-pharmaceutical, IOP-lowering therapy for patients with open angle glaucoma. Physicians shared how they are excited about being able to lower IOP safely in normal tension glaucoma patients with accompanying nocturnal IOP elevations.
Get the latest ophthalmology news delivered to your inbox every Friday.